BOB1, Mouse anti-Human, DyLight 755, Clone: BOB1/2424, Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer:  Novus Biologicals NBP275753IR

Catalog No. NB008869

Description

BOB1 Monoclonal antibody specifically detects BOB1 in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry (Paraffin).

Specifications

• Antigen: BOB1
• Clone: BOB1/2424
• Dilution: Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin
• Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
• Gene Symbols: POU2AF1
• Immunogen: Recombinant human BOB1 (POU2AF1) protein fragment (around aa 148-255) (exact sequence is proprietary)
• Monoclonal or Polyclonal: Monoclonal
• Purification Method: Protein A or G purified
• Regulatory Status: RUO
• Target Species: Human

• Applications: Western Blot,Flow Cytometry,Immunohistochemistry,Immunocytochemistry,Immunofluorescence,Immunohistochemistry (Paraffin)
• Conjugate: DyLight 755
• Format: Purified,Conjugated
• Gene Alias: B-cell-specific coactivator OBF-1, BOB-1, OBF-1, OBF1BOB1, OCAB, OCA-B, OCT-binding factor 1, POU class 2 associating factor 1, POU domain class 2, associating factor 1, POU domain class 2-associating factor 1, POU domain, class 2, associating factor 1
• Host Species: Mouse
• Isotype: IgG2b Kappa
• Primary or Secondary: Primary
• Quantity: 0.1 mL
• Storage Requirements: Store at 4°C in the dark.
• Test Specificity: BOB1 expression in a variety of established B-cell lines, representing different stages of B-cell development, has suggested a constitutive, B-cell-specific expression pattern. LP cells in nodular lymphocyte predominant Hodgkin lymphoma, because they are germinal center-derived, are consistently immuno-positive for BOB1. Conversely, only some cases of classical Hodgkin lymphoma show BOB1 immuno-reactivity within the Hodgkin and Reed-Sternberg cells. Expression of BOB1 has been reported in follicular center cell lymphoma, diffuse large B-cell lymphoma and some cases of acute myeloid leukemia. B-CLL, marginal zone lymphoma, and mantle cell lymphoma may show weak to moderate immunoreactivity.